We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+23.39%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$1.47B
AUM Growth
+$375M
Cap. Flow
+$157M
Cap. Flow %
10.72%
Top 10 Hldgs %
58.22%
Holding
55
New
7
Increased
25
Reduced
10
Closed
4

Top Buys

Rank Stock Value
1
PRQR icon
ProQR Therapeutics
PRQR
+$48.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$33.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$28.6M
4
PTCT icon
PTC Therapeutics
PTCT
+$19.9M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$19M

Top Sells

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$62.5M
2
RGNX icon
Regenxbio
RGNX
+$29.7M
3
SAGE
Sage Therapeutics
SAGE
+$15.9M
4
ASMB icon
Assembly Biosciences
ASMB
+$15.5M
5
QURE icon
uniQure
QURE
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 91.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$348M
$280M 19.13%
16,037,486
– –
PTCT icon
2
PTC Therapeutics
PTCT
$6.37B
$94.6M 6.46%
2,514,271
+591,925
+31% +$19.9M
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$91.2M 6.22%
6,223,036
+315,948
+5% +$3.63M
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$36.3B
$78.1M 5.33%
835,873
+396,375
+90% +$33.2M
BMY icon
5
Bristol-Myers Squibb
BMY
$127B
$72.8M 4.97%
1,525,464
+574,684
+60% +$28.6M
PRQR icon
6
ProQR Therapeutics
PRQR
$243M
$51.6M 3.52%
3,722,950
+3,274,809
+731% +$48.9M
MASI
7
DELISTED
Masimo
MASI
$50.3M 3.43%
363,569
+21,348
+6% +$2.68M
QTTB icon
8
Q32 Bio
QTTB
$450M
$48.2M 3.29%
96,484
+5,734
+6% +$2.56M
VCEL icon
9
Vericel Corp
VCEL
$2.3B
$43.6M 2.97%
2,487,922
+198,788
+9% +$3.64M
LIVN icon
10
LivaNova
LIVN
$4.3B
$42.3M 2.89%
435,136
-7,900
-2% -$738K
ACHN
11
DELISTED
Achillion Pharmaceuticals
ACHN
$40.7M 2.78%
13,749,383
– –
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.66B
$40.3M 2.75%
338,199
-27,712
-8% -$3.56M
MYOK
13
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$36.7M 2.51%
706,570
+411,672
+140% +$19M
AXNX
14
DELISTED
Axonics, Inc. Common Stock
AXNX
$36.5M 2.49%
1,524,030
+428,634
+39% +$7.78M
ADVM
15
DELISTED
Adverum Biotechnologies
ADVM
$32.8M 2.24%
625,684
– –
ESTA icon
16
Establishment Labs
ESTA
$2.72B
$31.9M 2.18%
1,325,539
+477,481
+56% +$12.7M
AGEN
17
Agenus
AGEN
$249M
$29.4M 2%
503,550
-12,834
-2% -$796K
ARWR icon
18
Arrowhead Research
ARWR
$12.1B
$28M 1.91%
1,528,213
-3,787,943
-71% -$62.5M
RGNX icon
19
Regenxbio
RGNX
$623M
$25.9M 1.77%
451,182
-599,063
-57% -$29.7M
LAB icon
20
Standard BioTools
LAB
$326M
$25.7M 1.75%
1,930,934
+1,046,699
+118% +$11M
SIBN icon
21
SI-BONE Inc
SIBN
$737M
$23.9M 1.63%
1,269,194
+464,867
+58% +$9M
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$22.9M 1.56%
312,093
+273,328
+705% +$18.6M
CNCE
23
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$20.4M 1.39%
1,688,448
+899,571
+114% +$13.3M
ABUS icon
24
Arbutus Biopharma
ABUS
$865M
$19.7M 1.35%
5,510,223
+1,174,477
+27% +$4.51M
APYX icon
25
Apyx Medical
APYX
$165M
$19.7M 1.35%
3,124,899
+733,001
+31% +$5.67M
1
2 3

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q1 2019 Portfolio in Review

As of Q1 2019, RTW Investments held 55 positions worth $1.47B, up 34% from $1.09B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

RTW Investments deployed $157M of net new capital in Q1 2019, opening 7 new positions and adding to 25 existing holdings. Its largest new stake was Wave Life Sciences: 436,777 shares worth $17M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Arrowhead Research, an estimated $62.5M trimmed.

  • RTW Investments's largest Q1 2019 buy was Wave Life Sciences: 436,777 shares worth $17M.
  • RTW Investments added most to ProQR Therapeutics in Q1 2019, an estimated $48.9M increase.
  • RTW Investments's biggest Q1 2019 reduction was Arrowhead Research, cutting an estimated $62.5M.
  • RTW Investments fully exited Sage Therapeutics in Q1 2019, selling an estimated $15.9M.
  • RTW Investments's ten largest holdings make up 58% of its $1.47B portfolio in Q1 2019.
  • RTW Investments opened 7 new positions and closed 4 in Q1 2019.
  • RTW Investments's portfolio value rose 34% quarter-over-quarter to $1.47B.

Based on RTW Investments's 13F filing for Q1 2019, filed 15 May 2019.